Channel Therapeutics Corporation
AMEX: CHRO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Francis Knuettel II,
- Employees
- 4
- Headquarters
- Freehold, United States
- IPO year
- 2024
- Market cap
- $8.9M
- Website
- https://channeltherapeutics.com
Loading CHRO…
Loading profile data…Frequently asked questions about CHRO
What does Channel Therapeutics Corporation (CHRO) do?
Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broad...
Where does CHRO trade?
Channel Therapeutics Corporation (CHRO) trades on the New York Stock Exchange Arca.
What sector is CHRO in?
Channel Therapeutics Corporation (CHRO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Channel Therapeutics Corporation?
Francis Knuettel II, is the chief executive officer of Channel Therapeutics Corporation (CHRO).
Where is Channel Therapeutics Corporation headquartered?
Channel Therapeutics Corporation is headquartered in United States.
Does CHRO pay a dividend?
Channel Therapeutics Corporation (CHRO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CHRO go public?
Channel Therapeutics Corporation (CHRO) completed its initial public offering in 2024.